Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
Chapter 2 Market Overview
- Alzheimer's Disease Overview
- Alzheimer's Disease Pathophysiology
- AD and Amyloid Cascade
- AD and Tauopathy
- AD and Neurotransmitter Systems
- Diagnosis of AD
- Cognitive Status Testing
- Brain Imaging
- Lumbar Puncture
- Blood-Biomarker Tests
- Genetic Testing
- Pharmaceutical Treatment of AD
Chapter 3 Market Dynamics
- Market Dynamics Snapshot
- Market Drivers
- Growing Incidence of AD
- High Unmet Need
- Growing Focus on Biomarkers in Diagnosis and Drug Development
- Increasing Public and Private investment in Neuroscience
- Growing Public Awareness and Early Diagnosis
- Large Number of Drugs in Late-Stage Clinical Trials
- Market Restraints
- High Costs of Diagnostics and Novel Therapies
- Patent Expirations of Branded Drugs and Emergence of Generics
- High Failure Rate in Drug Development
Chapter 4 Emerging Technologies and Developments
- Emerging Technologies/Trends
- Blood Tests for AD Screening and Diagnosis
- Disease Modifying Small-Molecule Drugs
- Re-purposed Drugs
- AI and Machine Learning
- Pipeline Analysis
- Overview
- Therapeutic Purpose Type
- Novel AD Therapeutics in Development in Phase 3
- By Target Type
- By Disease State
- Novel PET Radiotracers in Development
Chapter 5 Market Segmentation Analysis
- Segmentation Breakdown
- Market Analysis, by Test Type
- AD Biomarker Tests Market, by Test Type
- AD Therapeutics Market, by Therapeutic Purpose
- AD Therapeutics Market, by Drug Class
- AD Therapeutics Market, by Drug Type
- AD Therapeutics Market, by Disease Stage
- Geographic Breakdown
- Market Analysis, by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World (RoW)
Chapter 6 Competitive Intelligence
- AD Therapeutics
- Alzheimer's Generic Drug Market
- Alzheimer's Branded Drug Market
- Donepezil
- Rivastigmine
- Galantamine
- Memantine
- Combination Therapy (Memantine and Donepezil)
- AD Diagnostics
- Overview
- Product Launches/Approvals in the AD Diagnostics Market
List of Tables
Summary Table: Global Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 1: Brain Imaging Technologies and Application in the Alzheimer’s Context
Table 2: Common Methods for AD Detection
Table 3: Key Clinical Biomarkers Used in the Diagnosis of AD
Table 4: NIH Funding Estimates for Alzheimer’s Disease Research, 2017-2024
Table 5: Selected AD Biomarker-Focused Consortia
Table 6: Recent Therapeutic Programs Ceased Due to Failure in Clinical Trials
Table 7: Selected Blood Tests in Development for AD Screening/Diagnosis
Table 8: Disease Modifying Small Molecules AD Drug Candidates in Phase 3 Clinical Trials
Table 9: Disease Modifying Large Molecule AD Drug Candidates in Phase 3 Clinical Trials
Table 10: Treatments for AD-Related Neuropsychiatric and Behavioral Symptoms in Phase 3 Clinical Trials
Table 11: Cognitive Enhancer AD Drug Candidates in Phase 3 Clinical Trials
Table 12: Radiopharmaceuticals for CNS Imaging in Clinical Development
Table 13: Global Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 14: Comparison of Biomarker Tests
Table 15: FDA-Approved PET Radiopharmaceuticals for AD Diagnosis
Table 16: CSF-Based IVD Tests for AD
Table 17: Blood Tests for AD Diagnosis
Table 18: Global Market for AD Biomarker Tests, by Test Type, Through 2029
Table 19: FDA-Approved Drugs to Treat Cognitive Symptoms of AD
Table 20: FDA-Approved Drugs to Treat Non-Cognitive Symptoms of AD
Table 21: Global Market for AD Therapeutics, by Therapeutic Purpose, Through 2029
Table 22: FDA-Approved AChEIs
Table 23: FDA-Approved Anti-Amyloid Antibodies
Table 24: Selected Anti-Inflammatory and Neuroprotective Agents in Phase 3 Clinical Trials
Table 25: Global Market for AD Therapeutics, by Drug Class, Through 2029
Table 26: Anti-Amyloid Drugs in Phase 3 Clinical Development
Table 27: Neurotransmitter Modulars in Clinical Trials Phase 3
Table 28: Global Market for AD Therapeutics, by Drug Type, Through 2029
Table 29: Patent Information for AD Drugs
Table 30: Number of Companies with Active FDA Approval to Market AD drugs in the U.S.
Table 31: FDA-Approved AD Drugs and Their Indications
Table 32: Global Market for AD Therapeutics, by Disease Stage, Through 2029
Table 33: Global Market for AD Therapeutics and Diagnostics, by Region, Through 2029
Table 34: North American Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 35: North American Market for AD Therapeutics and Diagnostics, by Country, Through 2029
Table 36: U.S. Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 37: Canadian Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 38: Mexican Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 39: European Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 40: Europe Market for AD Therapeutics and Diagnostics, by Country, Through 2029
Table 41: German Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 42: French Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 43: U.K. Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 44: Italian Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 45: Rest of European Countries’ Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 46: Asia-Pacific Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 47: Asia-Pacific Market for AD Therapeutics and Diagnostics, by Country, Through 2029
Table 48: Chinese Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 49: Japanese Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 50: Rest of Asia-Pacific Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 51: RoW Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 52: Key Companies in the U.S. Alzheimer’s Generic Drug Market
Table 53: Commercially Available FDA-Approved Branded AD Drugs
Table 54: Companies with Active FDA Approval to Market Donepezil in the U.S.
Table 55: Companies with Active FDA Approval to Market Rivastigmine in the U.S.
Table 56: Companies with Active FDA Approval to Market Galantamine in U.S.
Table 57: Companies with Active FDA Approval to Market Memantine in the U.S.
Table 58: Companies with Active FDA Approval to Market Combination Therapy (Memantine and Donepezil) in the U.S.
Table 59: Selected Product Approvals/Launches in the AD Diagnostics Market, 2022-2024
Table 60: Information Sources in this Report
Table 61: Abbreviations Used in This Report
Table 62: AbbVie Inc.: Company Snapshot
Table 63: AbbVie Inc.: Financial Performance, FY 2022 and 2023
Table 64: AbbVie Inc.: Product Portfolio
Table 65: AbbVie Inc.: News/Key Developments, 2024
Table 66: Alpha Cognition: Company Snapshot
Table 67: Alpha Cognition: Financial Performance, FY 2022 and 2023
Table 68: Alpha Cognition: Product Portfolio
Table 69: Alpha Cognition: News/Key Developments, 2024
Table 70: ALZpath Inc.: Company Snapshot
Table 71: ALZpath Inc.: Product Portfolio
Table 72: ALZpath Inc.: News/Key Developments, 2023 and 2024
Table 73: Aurobindo Pharma: Company Snapshot
Table 74: Aurobindo Pharma: Financial Performance, FY 2022 and 2023
Table 75: Aurobindo Pharma: Product Portfolio
Table 76: Aurobindo Pharma: News/Key Developments, 2023
Table 77: Biogen: Company Snapshot
Table 78: Biogen: Financial Performance, FY 2022 and 2023
Table 79: Biogen: Product Portfolio
Table 80: Biogen: News/Key Developments, 2023 and 2024
Table 81: C2N Diagnostics: Company Snapshot
Table 82: C2N Diagnostics: Product Portfolio
Table 83: C2N Diagnostics: News/Key Developments, 2023 and 2024
Table 84: Corium LLC.: Company Snapshot
Table 85: Corium LLC.: Product Portfolio
Table 86: Corium LLC.: News/Key Developments, 2022 and 2023
Table 87: Diadem srl: Company Snapshot
Table 88: Diadem srl: Product Portfolio
Table 89: Diadem srl: News/Key Developments, 2022 and 2023
Table 90: Eisai Co. Ltd.: Company Snapshot
Table 91: Eisai Co. Ltd.: Financial Performance, FY 2022 and 2023
Table 92: Eisai Co. Ltd.: Product Portfolio
Table 93: Eisai Co. Ltd.: News/Key Developments, 2022-2024
Table 94: F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 95: F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 96: F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 97: F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2024
Table 98: H.U. Group Holdings Inc.: Company Snapshot
Table 99: H.U. Group Holdings Inc.: Financial Performance, FY 2022 and 2023
Table 100: H.U. Group Holdings Inc.: Product Portfolio
Table 101: H.U. Group Holdings Inc.: News/Key Developments, 2022-2024
Table 102: Laboratory Corporation of America Holdings: Company Snapshot
Table 103: Laboratory Corporation of America Holdings: Financial Performance, FY 2022 and 2023
Table 104: Laboratory Corporation of America Holdings: Product Portfolio
Table 105: Laboratory Corporation of America Holdings: News/Key Developments, 2022-2024
Table 106: Lilly: Company Snapshot
Table 107: Lilly: Financial Performance, FY 2022 and 2023
Table 108: Lilly: Product Portfolio
Table 109: Lilly: News/Key Developments, 2024
Table 110: Otsuka Holdings Co. Ltd.: Company Snapshot
Table 111: Otsuka Holdings Co. Ltd: Financial Performance, FY 2022 and 2023
Table 112: Otsuka Holdings Co. Ltd: Product Portfolio
Table 113: Otsuka Holdings Co. Ltd: News/Key Developments, 2023 and 2024
Table 114: Quest Diagnostics Inc.: Company Snapshot
Table 115: Quest Diagnostics Inc.: Financial Performance, FY 2022 and 2023
Table 116: Quest Diagnostics Inc.: Product Portfolio
Table 117: Quest Diagnostics Inc.: News/Key Developments, 2022-2024
List of Figures
Summary Figure: Global Market Shares of AD Therapeutics and Diagnostics, by Type, 2023
Figure 1: Hypothetical Models for Progression of Alzheimer’s Disease
Figure 2: Market Dynamics of Alzheimer’s Disease Therapeutics and Diagnostics
Figure 3: Breakdown of Global Aging Population (65 or Older) with Alzheimer’s-Associated Dementia, by Age Group, 2023
Figure 4: Breakdown of Dementia Cases in Japan, by Disease Type
Figure 5: Alzheimer’s and Related Dementia Research Funding at the NIH, 2013-2023
Figure 6: Potential Use of Blood-Based Biomarkers in Primary Care
Figure 7: Novel Industry-Sponsored AD Therapeutic Agents in Clinical Development, by Clinical Trial Phase
Figure 8: Share of Phase 3 AD Drug Development Pipeline, by Therapeutic Purpose Type
Figure 9: Share of Phase 3 AD Drug Development Pipeline, by Therapeutic Purpose Subtype
Figure 10: Number of AD Clinical Trials for Most Common Targets, by Phase, as of Oct. 2024
Figure 11: Share of Active Clinical Trials for AD, by Disease State, as of Oct. 2024
Figure 12: Global Market Shares of AD Therapeutics and Diagnostics, by Type, 2023
Figure 13: Global Market Shares of AD Biomarker Tests, by Test Type, 2023
Figure 14: Global Market Shares of AD Therapeutics, by Therapeutic Purpose, 2023
Figure 15: Global Market Shares of AD Therapeutics, by Drug Class, 2023
Figure 16: Global Market Shares of AD Therapeutics, by Drug Type, 2023
Figure 17: Alzheimer’s Disease (AD) Continuum
Figure 18: Global Market Shares of AD Therapeutics, by Disease Stage, 2023
Figure 19: Global Market for AD Therapeutics and Diagnostics, by Region, 2021-2029
Figure 20: Global Market Shares of AD Therapeutics and Diagnostics, by Region, 2023
Figure 21: North American Market Shares of AD Therapeutics and Diagnostics, by Type, 2023
Figure 22: North American Market Shares of AD Therapeutics and Diagnostics, by Country, 2023
Figure 23: European Market Shares of AD Therapeutics and Diagnostics, by Type, 2023
Figure 24: European Market Shares of AD Therapeutics and Diagnostics, by Country, 2023
Figure 25: Asia-Pacific Market Shares of AD Therapeutics and Diagnostics, by Type, 2023
Figure 26: Asia-Pacific Market Shares of AD Therapeutics and Diagnostics, by Country, 2023
Figure 27: RoW Market Shares of AD Therapeutics and Diagnostics, by Type, 2023
Figure 28: AbbVie Inc.: Revenue Share, by Business Unit, FY 2023
Figure 29: AbbVie Inc.: Revenue Share, by Country/Region, FY 2023
Figure 30: Aurobindo Pharma: Revenue Share, by Business Unit, FY 2023
Figure 31: Aurobindo Pharma: Revenue Share, by Country/Region, FY 2023
Figure 32: Biogen: Revenue Share, by Business Unit, FY 2023
Figure 33: Biogen: Revenue Share, by Country/Region, FY 2023
Figure 34: Eisai Co. Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 35: Eisai Co. Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 36: F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 37: F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 38: Laboratory Corporation of America Holdings: Revenue Share, by Business Unit, FY 2023
Figure 39: Lilly: Revenue Share, by Business Unit, FY 2023
Figure 40: Lilly: Revenue Share, by Country/Region, FY 2023
Figure 41: Otsuka Holdings Co. Ltd: Revenue Share, by Business Unit, FY 2023
Figure 42: Otsuka Holdings Co. Ltd: Revenue Share, by Country/Region, FY 2023
Figure 43: Quest Diagnostics Inc.: Revenue Share, by Business Unit, FY 2023
